Merck bets $700M on an antibody drug’s potential in immune diseases
Bio Pharma Dive
AUGUST 9, 2024
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
Bio Pharma Dive
NOVEMBER 14, 2024
The company is paying China-based biotech LaNova Medicines $588 million for the type of dual-pronged antibody drug that recently bested Keytruda in a clinical trial.
Clinical Trials 
312
312 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target
Bio Pharma Dive
MAY 18, 2021
The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.
Protein 339
339 
Dantari emerges with a new way to make cancer drug conjugates
Bio Pharma Dive
DECEMBER 8, 2022
As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.
Drugs 332
332 
FDA Animal Testing Phase-Out Targets Monoclonal Antibodies
XTalks
APRIL 14, 2025
The roadmap initially targets monoclonal antibodies (mAbs) and similar biologic therapies drugs engineered to bind precise disease targets before expanding to other drug classes. Ultimately, the FDA hopes to deliver safer medicines to patients more quickly while lowering development costs.
Antibody 59
59 
J&J wins approval of new kind of multiple myeloma drug
Bio Pharma Dive
OCTOBER 26, 2022
The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.
Protein 297
297 
Sanofi, Regeneron surge as Dupixent scores in COPD trial
Bio Pharma Dive
MARCH 23, 2023
The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.
Antibody 293
293 
Seagen, Genmab win speedy FDA approval for cervical cancer drug
Bio Pharma Dive
SEPTEMBER 21, 2021
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.
FDA Approval 291
291 
Navigator gains $100m in Series A funding for antibody therapeutics
Pharmaceutical Technology
AUGUST 28, 2024
Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.
Antibody 130
130 
IgY antibody technology against SARS-CoV-2 unveiled
Pharma Mirror
JANUARY 29, 2022
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily. Shenzhen) and a local precision medicine research institute.
Antibody 130
130 
Lilly to buy Versanis, adding to obesity drug pipeline
Bio Pharma Dive
JULY 14, 2023
billion to acquire the private biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines. The pharma will pay up to $1.9
Antibody 246
246 
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
Bio Pharma Dive
OCTOBER 9, 2020
The medicine, a concentrated infusion of blood antibodies, is different than the convalescent plasma that was recently cleared for emergency use by the FDA.
Antibody 242
242 
Datroway’s Approval in Breast Cancer Solidifies Daiichi Sankyo’s Leadership in ADCs
XTalks
JANUARY 21, 2025
The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.
Antibody 105
105 
Disc and Mabwell sign deal for licence to antibodies portfolio
Pharmaceutical Technology
JANUARY 23, 2023
Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis. development and commercial milestones. development and commercial milestones.
Antibody 130
130 
Innovation in immuno-oncology: Leading companies in tumour antibody serum compositions
Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.
Antibody 147
147 
A biotech startup with big-name backers aims to create new cancer medicines
Bio Pharma Dive
APRIL 14, 2023
Newly launched TORL BioTherapeutics wants to develop a variety of antibody drugs, and comes equipped with $158 million as well as a close partnership with the lab of pioneering breast cancer researcher Dennis Sloman.
Medicine 184
184 
Sanofi pays IGM $150M, continuing search for better antibody drugs
Bio Pharma Dive
MARCH 29, 2022
The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines.
Antibody 130
130 
Covid evolution wipes out another antibody treatment, threatening the country’s medicine cabinet
STAT News
NOVEMBER 30, 2022
The Food and Drug Administration on Wednesday ended its emergency authorization for the only remaining Covid-19 antibody therapy cleared for use, saying variants that render it ineffective are now dominant in the United States. have been growing in prevalence. Read the rest…
Antibody 111
111 
Biocytogen and ADC to evaluate antibodies for three cancer targets
Pharmaceutical Technology
NOVEMBER 27, 2022
Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.
Antibody 130
130 
Gemini enters business combination deal with Disc Medicine
Pharmaceutical Technology
AUGUST 11, 2022
Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US. To back the merger, Disc raised funds worth $53.5m
Medicine 147
147 
Sanofi unveils global health brand for medicines supply
Pharmaceutical Technology
JULY 5, 2022
Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world. The post Sanofi unveils global health brand for medicines supply appeared first on Pharmaceutical Technology.
Branding 147
147 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. MGD024 is an investigational bispecific antibody that attaches to CD123 and CD3. The post Gilead partners with MacroGenics for bispecific antibody development appeared first on Pharmaceutical Technology.
Antibody 130
130 
Celltrion’s Avtozma Receives FDA Approval, Making it the Third Actemra Biosimilar to Hit the Market
XTalks
FEBRUARY 5, 2025
That was followed by a full approval for the same patient subset in December 2022, making it the first FDA-approved monoclonal antibody to treat COVID-19. Avtozma was submitted for regulatory approval to the FDA in January 2024 and the European Medicines Agency (EMA) in February 2024.
FDA Approval 102
102 
Alentis Therapeutics raises funds to develop medicines for CLAUDIN-1
Pharmaceutical Technology
APRIL 13, 2023
Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.
Medicine 130
130 
SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine
Pharmaceutical Technology
MAY 30, 2023
SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. It was granted based on data from the Phase III study, which demonstrated that the vaccine induced neutralising antibodies against the SARS-CoV-2 original strain.
Vaccination 298
298 
Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK
Pharma Mirror
APRIL 18, 2023
Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
Licensing 130
130 
J&J to acquire ADC drug developer Ambrx for $2B
Bio Pharma Dive
JANUARY 8, 2024
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
Drugs 196
196 
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.
Antibody 130
130 
Monoclonal antibody treatment for malaria shows encouraging results
STAT News
AUGUST 3, 2022
An experimental antibody treatment prevented malaria in the majority of participants in a small but important new study , providing a measure of hope in the effort to lower the burden of the disease worldwide. Read the rest…
Antibody 105
105 
Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment
Pharmaceutical Technology
MAY 8, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.
Antibody 130
130 
Sanofi, AstraZeneca win EMA support for RSV drug in babies
Bio Pharma Dive
SEPTEMBER 16, 2022
If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants.
Antibody 190
190 
China’s NMPA clears Transcenta’s IND for solid tumour treatment
Pharmaceutical Technology
JANUARY 4, 2023
TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity.
Antibody 242
242 
STAT+: ‘Practice changing’: Antibody treatment benefits leukemia patients receiving bone marrow transplant
STAT News
FEBRUARY 21, 2023
An experimental antibody that delivers lethal radiation directly to the bone marrow improved the outcomes of stem cell transplants for older patients with relapsed leukemia — and may change the way transplant medicine is practiced.
Antibody 105
105 
US buys Lilly COVID antibody, as effectiveness questions remain
pharmaphorum
OCTOBER 28, 2020
The US has said that patients will have no out-of-pocket costs for the medicine – echoing a promise by Lilly CEO Dave Ricks – although healthcare facilities may charge a fee for the product’s administration. . Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live. “As
Antibody 104
104 
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
Bio Pharma Dive
JUNE 21, 2024
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
Licensing 167
167 
Genmab and argenx team up to engineer novel antibody therapies
Pharmaceutical Technology
APRIL 17, 2023
Pharmaceutical company Genmab is entering a partnership with argenx to develop antibody therapies for oncology and immunology. This collaboration is being made to combine the companies’ capabilities to develop novel therapeutic antibodies with applications in the two disease areas.
Antibody 130
130 
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
Bio Pharma Dive
APRIL 3, 2024
The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.
Antibody 184
184 
At ESMO, three studies show promise of antibody-drug conjugates in breast cancer
pharmaphorum
MAY 30, 2022
pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. That antibody-drug conjugate then docks on the cancer cell receptor.
Antibody 116
116 
EC grants marketing authorisation for Sandoz’s biosimilar Hyrimoz
Pharmaceutical Technology
APRIL 3, 2023
Hyrimoz has been approved for use in all the indications covered by the reference medicine Humira, including plaque psoriasis, rheumatic diseases, ulcerative colitis, Crohn’s disease, uveitis and hidradenitis suppurativa. Its reference medicine, Humira, initially received approval with an adalimumab 50 mg/mL concentration.
Marketing 264
264 
Old mice regain leg strength after antibody treatment
Medical Xpress
NOVEMBER 17, 2022
But a study by researchers at Stanford Medicine shows that old mice regain the leg muscle strength of younger animals after receiving an antibody treatment that targets a pathway mediated by a molecule called CD47.
Antibody 98
98 
Let's personalize your content